Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study is designed to demonstrate the safety and efficacy of a second transrectal
intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH)
who previously received an injection of NX-1207 in an earlier U.S. clinical trial of NX-1207.